Gastrointestinal stromal tumors.

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90% of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80%. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.

Original languageEnglish (US)
Pages (from-to)485-491
Number of pages7
JournalCurrent Treatment Options in Oncology
Volume2
Issue number6
StatePublished - Dec 2001

Fingerprint

Gastrointestinal Stromal Tumors
Neoplasms
Therapeutics
Leiomyosarcoma
Protein-Tyrosine Kinases
Recurrence
Drug Therapy
Mutation
Pharmaceutical Preparations
Imatinib Mesylate

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gastrointestinal stromal tumors. / Blanke, Charles; Eisenberg, B. L.; Heinrich, Michael.

In: Current Treatment Options in Oncology, Vol. 2, No. 6, 12.2001, p. 485-491.

Research output: Contribution to journalArticle

@article{921286ce0c7e4e2ca8f9fb0a7055a729,
title = "Gastrointestinal stromal tumors.",
abstract = "Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90{\%} of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60{\%} and overall tumor control rates of 85{\%}. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80{\%}. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.",
author = "Charles Blanke and Eisenberg, {B. L.} and Michael Heinrich",
year = "2001",
month = "12",
language = "English (US)",
volume = "2",
pages = "485--491",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "6",

}

TY - JOUR

T1 - Gastrointestinal stromal tumors.

AU - Blanke, Charles

AU - Eisenberg, B. L.

AU - Heinrich, Michael

PY - 2001/12

Y1 - 2001/12

N2 - Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90% of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80%. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.

AB - Gastrointestinal stromal tumors (GISTs) are mesenchymal gut tumors that differ dramatically from other histologically similar neoplasms, such as leimomyomas, leiomyosarcomas (LMS), and neural tumors. Complete surgical removal remains the best current therapy for GISTs, but even major resections are associated with recurrence in approximately 90% of cases. GISTs are remarkably resistant to irradiation and standard chemotherapy; there is no role for treatment with those modalities. Treatment of advanced GIST patients with STI571, a novel selective tyrosine kinase inhibitor, results in remission rates that approach 60% and overall tumor control rates of 85%. Selected groups of patients, as based on tumor mutational status, have response rates as high as 80%. To date, STI571 therapy remains the only systemic treatment for GISTs to have meaningful clinical activity. Though other molecularly targeted therapies exist in oncology (eg, trastuzumab), STI571 is one of the first that applies a drug specifically designed to inhibit the product of a constitutively-activating mutation that drives pathogenesis of a solid tumor. Its use can serve as a paradigm for designing molecularly targeted therapies for other malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0035749620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035749620&partnerID=8YFLogxK

M3 - Article

C2 - 12057094

AN - SCOPUS:0035749620

VL - 2

SP - 485

EP - 491

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 6

ER -